Abstract: Hyperbaric oxygen (HBO) treatment has been reported to cause amelioration of clinical symptoms in patients with multiple sclerosis (MS). We have treated 10 MS patients with hyperbaric oxygen (100% O2 at 2 atmospheres absolute for 90 min daily for a total of...
Abstract: Research into patients' perspectives on treatments, in concentrating on their compliance with medically prescribed regimens, have taken bio-medicine's evaluation of therapeutic efficacy and benefit for granted. This paper suggests that the clinical trial,...
Abstract: Aita (1988). Hyperbaric oxygen and multiple sclerosis--a review. The Nebraska medical journal, 1988 Aug;73(8):266-8. https://www.ncbi.nlm.nih.gov/pubmed/3050559
Abstract: Preliminary clinical examinations comprised 16 patients suffering from multiple sclerosis, the mean duration of the disease 9.33 years, of the manifestations at different stages of the development--evaluated on the basis of Kurtzke scale. The patients were...
Abstract: Inclusion of subjective measures in clinical trials has raised questions concerning the basis on which their results may be compared with medical findings. Central problems relate to the status of such measures as indicators of 'real' change and to...
Abstract: Multimodal evoked potentials (EPs) were obtained serially in 57 patients with multiple sclerosis enrolled in a double-blind, controlled study of hyperbaric oxygen. We encountered drawbacks in the use of EPs in monitoring effects of a treatment for chronic...
The long term results are reported of a trial involving 120 patients with chronic multiple sclerosis who were randomised to receive either 100% oxygen at 2 atmospheres absolute (ATA) for 90 minutes daily for 20 sessions or placebo therapy with air using a simulated compression procedure. The previous finding of subjective improvement in bowel/bladder function at the end of treatment was not confirmed by objective urodynamic assessment. The treatment did not alter disease progression as measured by the Kurtzke disability status scale nor did it alter the rate of acute relapse. There was less deterioration in cerebellar function at one year in the treated patients as measured by the Kurtzke functional systems scale. No other differences were found between the two groups. Psychometric tests and measurements of lymphocyte sub-populations showed no treatment related effects. Evoked potential studies showed no improvements but there was a significant reduction in amplitude of the visual evoked potential in the treated patients at the end of therapy. This might indicate a reversible degree of retinal damage induced by oxygen toxicity.
